drugset / Trial / NCT05333250

Modafinil to Improve Fatiguability

NCT05333250

RandomizedParallel-groupTriple-blindTreatment

Summary

Cancer-related fatigue (CRF) and cancer-related cognitive impairment (CRCI) are among the most commonly reported disabling symptoms experienced by patients with advanced cancer. However, there are currently limited evidence-based pharmacologic interventions available. The investigators will conduct a Vanguard Randomized Clinical Trial (RCT) to estimate the effect of modafinil in managing CRF and CRCI, and to test the feasibility of carrying out the study.

Timeline

Start
2026-01-22
Primary completion
2027-10
Completion
2028-03

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Modafinil Small molecule 200 mg